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E
pigenomics is one of the 
many ‘omics’ that is being 
talked about in the wake of 
the Human Genome Project. But 
what is an epigenome, and why have 
the Wellcome Trust Sanger Institute 
(Hinxton, United Kingdom) and 
Epigenomics AG (Berlin, Germany) 
recently announced the launch of the 
Human Epigenome Project (HEP), 
a five-year undertaking during which 
DNA methylation sites throughout 
the human genome will be mapped? 
The HEP is the brainchild of 
immunogeneticist Stephan Beck of the 
Sanger Institute and Alexander Olek, 
chief executive officer of Epigenomics 
AG. The Human Genome Project, 
explains Olek, ‘provided the blueprint 
for life, but the epigenome will tell us 
how this whole thing gets executed’, 
what determines when and where genes 
are switched on and off to produce a 
person. And knowing more about the 
human epigenome may provide clues 
to what goes wrong in cancer and other 
diseases.
What Is Epigenetics?
Most people have a fair idea of what 
is meant by genetics. They know that 
characteristics such as eye colour are 
specified by the DNA sequence within 
their genome. But not everything is 
that simple. For example, genetically 
identical twins can be very different. 
‘One might be normal, while the 
other is autistic’, explains chromatin 
researcher David Allis (Rockefeller 
University, New York, United States). 
‘We can’t explain that on the basis 
of pure genetics because the DNA is 
identical. Something else must be at 
play’.
That ‘something else’ is chemical 
modifications of genes that are 
heritable from one cell generation 
to the next and that affect gene 
expression but do not alter the DNA 
sequence. Epigenetic modifications can 
affect the DNA itself or the proteins 
that package the DNA into chromatin. 
Developmental geneticist Wolf Reik 
(The Babraham Institute, Cambridge, 
United Kingdom) describes these 
modifications as ‘red and green traffic 
lights that are superimposed on top of 
the genome to tell the genes whether 
they should be active or inactive’. For 
individual cells, this code on top of a 
code helps to determine whether a cell 
is a blood cell, a fat cell, or something 
else. And in the case of monozygotic 
twins, unexpected differences may 
result from chance variations in this 
superimposed code (Box 1).
The study of these modifications—
what they are, how they are laid 
down, and the processes that they 
control—is the field of research known 
as epigenetics. An epigenome is the 
description of these modifications 
across the whole genome, but unlike 
the genome DNA sequence, each 
organism has multiple epigenomes—
for example, in different cell types—
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Box 1. The Same but Different
Geneticist Emma Whitelaw (University of Sydney, Australia) studies phenomena in mice similar 
to those seen in human monozygotic twins, whereby genetically identical individuals can look 
or behave very differently. About a decade ago, she explains, ‘we noticed that in a litter of mice 
that had all stably inherited a transgene at a specific locus, some mice expressed the transgene, 
but others didn’t’. This variable gene expressivity in genetically identical animals suggested that 
some kind of epigenetic mark had occurred differentially between individuals by chance. Similarly, 
identical mice carrying the agouti viable yellow coat colour gene can range in colour from yellow 
through mottled to brown, depending on whether the gene is expressed or not. And while a 
mutation in the axin gene called axin-fused produces mice with kinky tails, the degree of kinkiness 
varies among genetically 
identical littermates (Figure 1). 
For all these mice, Whitelaw 
has discovered that the 
mysterious epigenetic marks 
responsible for variable 
expressivity are inherited 
between sexual generations. 
So, in the case of the agouti 
viable yellow mice, yellow mice 
have more yellow offspring 
than mottled or brown 
offspring. Variable expressivity 
may be a quicker way to deal 
with environmental change 
than DNA mutation and, 
suggests Whitelaw, it may 
be that variable expressivity 
is involved in some way in 
evolution. 
DOI: 10.1371/journal/pbio.0000082.g001
Figure 1. Spot the Difference: Same Genes but a Different Kink 
in the Tail 
(Photograph courtesy of Emma Whitelaw, University of 
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that may change during its lifetime in 
response to environmental cues.
DNA Methylation 
Methylated DNA was the first 
epigenetic mark to be discovered. 
That this epigenetic modification is 
important is suggested by the waves 
of demethylation and de novo (new) 
methylation that occur at specific 
stages during the development of an 
animal from a fertilised egg. Soon 
after fertilisation, there is a massive 
active loss of methylation from the 
paternal genome, explains Reik. At the 
same time, the maternal genome loses 
some methyl groups through passive 
demethylation. ‘We think this process 
erases all the epigenetic memory in the 
gametes [sperm and egg cells] except 
for some special imprinted genes whose 
expression depends on whether they 
are of maternal or parental origin’, says 
Reik. Later in development, widespread 
de novo DNA methylation occurs in a 
process known as reprogramming. De 
novo methylation rarely occurs after 
an early developmental event known 
as gastrulation, except in cancer cells 
where special unmethylated regions 
of the genome, known as CpG islands, 
often become methylated.
 ‘People generally agree that DNA 
methylation is important for imprinting 
and reprogramming’, says Reik, ‘but 
not everyone agrees that it plays a role 
in DNA activation and inactivation 
during development’,  a role first 
proposed more than 25 years ago. 
‘People are still hesitant about saying 
that DNA methylation is important 
in making sure the right genes are 
expressed in the right cells at the right 
time because until recently we have 
had relatively few good examples’, 
says DNA methylation expert Adrian 
Bird (The Wellcome Trust Centre 
for Cell Biology, Edinburgh, United 
Kingdom). Many people have reported 
correlations between methylation states 
and gene activity but, says Reik, ‘you 
can look at such correlations until 
the cows come home and it tells you 
nothing about causality’.
The HEP Pilot
Even given the doubts about the 
exact role of DNA methylation, Bird, 
Allis, and Reik believe that mapping 
methylation patterns across the 
human genome, which is what the 
HEP plans to do, is a worthwhile albeit 
enormous undertaking. ‘Knowing the 
methylation sequence’, says Bird, ‘will 
be an essential backdrop to future 
research on DNA methylation and its 
biological effects’. Allis agrees that 
DNA methylation is an important part 
of epigenetic marking, but ‘although 
mapping DNA methylation patterns is 
the logical and good place to start, by 
its lonesome it won’t explain the whole 
epigenetic phenomenon’. 
Beck and Olek began thinking about 
mapping the human epigenome more 
than five years ago. Even as long ago 
as 1998, explains Olek, ‘it was pretty 
natural to be thinking about what 
would come after the Human Genome 
Project, and Stephan believed that 
it had to be methylation sequencing 
because that has the potential to tell 
us about the hundreds of genomes we 
really have’.
In October 2000, the Human 
Epigenome Consortium (the Sanger 
Institute, Epigenomics AG, and the 
Centre National de Génotypage in 
Evry, France) started a European 
Union-funded pilot project to map 
the methylation sites within the major 
histocompatibility complex (MHC) 
region in seven different human 
tissues. Rather than look at all the 
DNA methylation sites throughout the 
entire MHC region, the consortium 
set out to look at the 150 expressed 
genes within this region, explains Beck. 
For each gene, the scientists chose 
two areas to analyse for methylation, 
each about 500 basepairs long. ‘One 
window was in what we thought was 
the promoter region’, says Beck, 
‘and the other corresponded to the 
most CpG-rich region in the gene’. 
The promoter regions are the places 
where the elements that control gene 
expression are often located, and DNA 
methylation occurs at cytosine residues 
within CpG motifs, hence the choice of 
CpG-rich regions.
The methylation status of more 
than 100, 000 sites was determined 
during the three-year pilot study and 
the results analysed to show where 
there were methylation differences 
in the MHC between different 
tissues (Figure 2). ‘We found major 
methylation differences between loci 
and between tissues’, says Beck, ‘and 
we are particularly interested in what 
we call methylation variable positions 
(MVPs), which we believe will advance 
our ability to understand and diagnose 
human disease’.  Olek echoes Beck’s 
satisfaction with the results to date. ‘We 
DOI: 10.1371/journal/pbio.0000082.g002
Figure 2. Example of HEP Methylation Data for the BAT8 Gene, an MHC-Linked Histone 
Methyltransferase
In this case, two regions marked in red were analysed in 31 samples (rows) from seven 
tissues (blocks of rows). The predicted structure of the gene is shown below with 
coloured boxes indicating the exons.  As part of the launch of the HEP on October 7, 
2003, these data and others, together with experimental details of the pilot study, were 
released at www.epigenome.org.Volume 1  |  Issue 3  |  Page 318 PLoS Biology  |  http://biology.plosjournals.org
can see that there is hidden treasure in 
the data that needs mining, and that 
treasure is obviously going to get much 
bigger when we sequence the whole 
thing’, he says.
On to the Full HEP: A Public/Private 
Initiative
That endeavour—the mapping of 
DNA methylation sites in all 30,000 
human genes in around 200 samples—
is now underway. ‘These will be very 
carefully chosen’, says Olek, ‘with the 
help of additional academic centres 
who we hope will join our consortium’. 
Sample preparation and amplification 
will be done at Epigenomics AG, the 
Sanger Institute will do the sequencing 
and raw data analysis, and then the data 
will be jointly evaluated and mined, ‘a 
huge collaborative experiment’, says 
Olek.
The Wellcome Trust and 
Epigenomics AG are jointly funding 
phase I of the HEP, thus avoiding a 
rerun of the situation that occurred in 
the Human Genome Project, in which 
a commercial company and a public 
effort ended up competing with each 
other. An agreement has been drawn 
up that ensures that both partners 
benefit from the collaboration, and 
all the data generated will be publicly 
available through the Internet in 
accordance with the consortium’s data 
release policy (www.epigenome.org and 
www.sanger.ac.uk/epigenome).
Histone Modifications and 
Epigenetic Landscaping
DNA methylation is not the only 
epigenetic mark. There are also a 
staggering number of acetylation and 
methylation marks on the histones—
the proteins that bind DNA to form 
chromatin. Histone modifications 
alter the chromatin structure and thus 
regulate gene expression, says Allis, 
‘and somehow the cell exploits each 
and every one of these in a meaningful 
way’. Recently, a link between DNA 
methylation and histone methylation 
was uncovered, a finding that Reik 
says has ‘galvanised the field’.  In 
Neurospora and Arabidopsis, he explains, 
there is now good evidence that 
histone modification puts down some 
sort of mark that is read by a series 
of binding proteins, including the 
enzymes that methylate DNA. How the 
positional specificity of the first mark is 
determined remained a mystery until 
the end of 2002, when the first reports 
appeared suggesting that in Arabidopsis 
small RNAs might be involved. The 
small RNAs are thought to bind to 
‘complementary’ sequences in DNA 
and somehow target the region for 
epigenetic modification. Whether 
similar mechanisms exist in animals 
remains to be seen.
To answer this and other epigenetic 
puzzles, scientists are organising 
themselves into collaborative networks 
to maximise progress. In Europe, for 
example, Thomas Jenuwein (Research 
Institute of Molecular Pathology, 
Vienna, Austria) is in negotiation 
with the European Commission over 
the establishment of a Network of 
Excellence in epigenetic research. 
This ‘Epigenome Network’, which 
will focus on epigenetic mechanisms, 
‘will allow us to build a long-lasting 
platform to bring together colleagues 
working on epigenetics in Europe 
and make this area of research very 
strong’, says Jenuwein. Negotiations 
with the European Commission for 
an anticipated 12 million of funding 
over five years should be completed 
soon, and, if all goes well, the Network 
should start work in Spring 2004. 
The Network will not itself fund any 
epigenome mapping projects like 
HEP, says Jenuwein, but will build 
strong links with scientists involved in 
mapping the ‘epigenetic landscape’, 
the pattern of DNA methylations and 
histone modifications. 
Just an Academic Exercise?
Epigenetics is a fascinating 
phenomenon, but why are funding 
bodies keen to fund expensive 
collaborative enterprises like the 
HEP and the Epigenome Network? 
One hope is that an understanding 
of how cells execute their genomes 
normally will provide important clues 
about what goes wrong in diseases 
such as cancer, in which, says Bird, 
‘methylation has gone a bit wonky in 
various respects. In particular, CpG 
islands, regions of the genome that 
are normally nonmethylated, get 
methylated, and in some cases this 
seems to shut off tumour suppressor 
expression’. Loss of tumour suppressor 
function can remove the controls that 
normally restrict cell division, leading 
to the unrestrained cell growth that is 
a characteristic of cancer. There are 
also alterations in histone acetylation 
patterns in cancer, and cataloguing 
these epigenetic changes in different 
tumours may provide a way to tag 
cancers to help clinicians to choose the 
best therapeutic regimen for individual 
patients. Epigenetic changes may also 
provide scope for new therapeutic 
approaches, says Allis. If a gene is 
inappropriately switched off during 
cancer development, he explains, 
‘maybe if we could de-silence it, we 
could reverse tumour development’. 
Bird agrees that reversing epigenetic 
marks in this way is an experiment 
that has to be done. But, he asks, 
‘is epigenetics the Achilles heel of 
cancer, or are there too many genetic 
changes that are hard-wired to be able 
to reverse it simply by interfering with 
epigenetics?’
A better understanding of 
epigenetics might also improve the 
efficiency of cloning animals from 
somatic cells (reproductive cloning). 
It is very hard to clone animals from 
somatic cells and, says Bird, ‘the 
more you look at the surviving cloned 
animals in molecular terms, the 
odder they look’. Reik suggests that 
this could indicate that epigenetic 
reprogramming—the process needed 
to turn a somatic cell back into a 
totipotent cell—is very inefficient. ‘We 
have some evidence that there is a 
link between the success of epigenetic 
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reprogramming and that of cloning, 
and we really have to understand 
the reprogramming process to get 
reproductive cloning to work’, says 
Reik. ‘At the moment the whole 
process is a black box’. Because of 
this, many scientists argue that human 
reproductive cloning, leaving aside the 
ethical concerns about it, simply isn’t 
a safe option at present, a concern 
reflected in the recent call by 60 
scientific academies for a ban on its 
development. 
Epigenetics then, both at the level of 
unravelling mechanisms and mapping 
epigenomes and at the applied level, 
is an exciting area of research. A far 
cry from the situation 10 years ago, 
says Reik, ‘when the field had the 
smell of something esoteric that no 
one really understood and whose 
significance was not clear. Now it is one 
of the mainstream exciting areas of 
post-genomic biology’, he concludes, 
and one which will hopefully yield to 
the might of large consortia like the 
Epigenome Network and the HEP. 
Where to Find Out More
The Human Epigenome Project
Information on the project, publications, and up-
to-date data releases are posted at http:⁄⁄
www.epigenome.org. 
DNA Methylation
The DNA Methylation Society homepage provides 
more details on DNA methylation at http:⁄⁄
dnamethsoc.server101.com.
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